Boston Scientific (NYSE:BSX) has struggled to get U.S. insurers on board with its Alair bronchial thermoplasty treatment system for asthma patients, according to a new report from Bloomberg Business published last Friday.
Concerns over the risk of complications, the availability of inexpensive asthma drugs and the potential for the disease to clear up on its own are at the heart of what is keeping insurers away, Bloomberg reported.
Help employers find you! Check out all the jobs and post your resume.
